Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects

  title={Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects},
  author={Abhinay D. Joshi and Michael J. Pontecorvo and Chris M. Clark and Alan Carpenter and Danna Jennings and Carl H. Sadowsky and Lee P. Adler and Karel D. Kovnat and John Seibyl and Anupa K. Arora and Krishnendu Saha and Jason Burns and Mark J. Lowrey and Mark A. Mintun and Daniel M. Skovronsky},
  journal={The Journal of Nuclear Medicine},
  pages={378 - 384}
The objectives of this study were to examine the effective dose range and the test–retest reliability of florbetapir F 18 using, first, visual assessment by independent raters masked to clinical information and, second, semiautomated quantitative measures of cortical target area to cerebellum standardized uptake value ratios (SUVr) as primary outcome measures. Visual ratings of PET image quality and tracer retention or β-amyloid (Aβ) binding expressed as SUVrs were compared after intravenous… 

Figures and Tables from this paper

Imaging characteristics and safety of florbetapir (18F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer’s disease
The reliability of both qualitative and quantitative assessments of florbetapir (18F) in this study population provides support for potential use in clinical settings in Japan and indicates that amyloid positivity increased with diagnostic category (CN < MCI <-AD) and are consistent with expected rates of amyloids positivity among individuals with clinical diagnoses of AD and MCI.
Relationship between F-18 florbetapir uptake in occipital lobe and neurocognitive performance in Alzheimer’s disease
Occipital amyloid uptake is associated with clinically advanced AD, and is inversely correlated with neurocognitive performance and may be useful for evaluating AD severity.
PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders
The results of this study show significant differences in both florbetapir and florbenazine imaging that are consistent with expected pathology and correlated significantly with cognitive impairment in DLB patients.
Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods
PiB and florbetapir retention ratios were strongly associated in the same individuals, and this relationship was consistent across several data analysis methods, despite scan–rescan intervals of more than a year.
Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging
These results illustrate the comparability of Florbetapir and PIB in unrelated but matched patient populations and the role of amyloid PET imaging becomes increasingly important with increasing age in the diagnostic assessment of clinically impaired patients.
Quantification of [18F]florbetapir: A test–retest tracer kinetic modelling study
  • S. Golla, S. Verfaillie, A. Lammertsma
  • Medicine
    Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism
  • 2018
In vivo kinetics of [ 18F]florbetapir could best be described by a reversible two-tissue compartmental model and [18F] flor betapir BPND can be reliably estimated using an SRTM.
Reference region selection and the association between the rate of amyloid accumulation over time and the baseline amyloid burden
It is suggested that SUVR relative to WM may be more robust to changes in CBF, and thus fitter for sensitive detection of amyloid accumulation in intervention studies.
Evaluation of amyloid status in a cohort of elderly individuals with memory complaints: validation of the method of quantification and determination of positivity thresholds
RACHEL including PVEC and a combination of the whole cerebellum and the pons as a reference region allowed the best discrimination between NEC and AD participants, and clearly discriminated between NEC with negative amyloid status and patients with clinical AD.
Measurement of Longitudinal β-Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios
The accurate measurement of β-amyloid (Aβ) change using amyloid PET imaging is important for Alzheimer disease research and clinical trials but poses several unique challenges. In particular,


Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease.
The findings of this analysis confirm the ability of florbetapir-PET SUVRs to characterize amyloid levels in clinically probable AD, MCI, and OHC groups using continuous and binary measures of fibrillar Aβ burden.
Use of florbetapir-PET for imaging beta-amyloid pathology.
Evidence is provided that a molecular imaging procedure can identify β-amyloid pathology in the brains of individuals during life and for the prediction of progression to dementia.
In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18)
18F-AV-45 was well tolerated, and PET showed significant discrimination between AD patients and HCs, using either a parametric reference region method (DVR) or a simplified SUVR calculated from 10 min of scanning 50–60 min after 18F- AV-45 administration.
Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis.
Of the simplified methods for PIB analysis examined, CAR90 provided DVR measures that were most comparable to ART90; CER90 was the most reproducible and SUVR90 produced the largest effect size.
[11C]PIB in a nondemented population
Elevated [11C]PIB binding in nondemented subjects suggests that [11 C]P IB amyloid imaging may be sensitive for detection of a preclinical Alzheimer disease state.
Test-retest variability of quantitative [11C]PIB studies in Alzheimer’s disease
Parametric SRTM2 with the cerebellum as reference tissue is the method of choice for quantitative analysis of [11C]PIB PET studies and has been found to be the best method based on the simplified reference tissue model for test-retest variability.
Phase 1 Study of the Pittsburgh Compound B Derivative 18F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease
18F-flutemetamol uptake can be readily quantified and warrants further studies to validate this 18F-labeled derivative of PiB as a biomarker for Aβ amyloidosis.
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
It is found that rate-of-change determinations are less reliable when the observation period is 1 year or less, dementia progression may be nonlinear when described by certain measures, and that simple change scores do not accurately characterize the rate of decline.